TAK-653 (also called osavampator or NBI-1065845) is an investigational AMPA-receptor positive allosteric modulator designed to enhance glutamate signaling without the seizure liability of older ampakines. This reference covers its mechanism, the real Phase 1 and Phase 2 clinical evidence, how it differs from ketamine and older ampakines, community-reported use, honest safety framing, and where to source it. Research-use-only; not an approved drug.
TAK-653 is an investigational AMPA-receptor positive allosteric modulator (PAM), a molecule that turns up the volume on the brain's main excitatory glutamate signal, but only when glutamate is already being released. It was engineered by Takeda to boost AMPA-receptor signaling without directly switching the receptor on, which is what gave older ampakines their seizure problems. It is now in late-stage clinical development for depression under the name osavampator (also coded NBI-1065845 by Neurocrine), and it is not approved by any regulator for any use.
This is an education and price-comparison reference, not medical advice. TAK-653 is an experimental compound sold research-use-only. Nothing here is a recommendation to take it.
What TAK-653 actually is
TAK-653 is a selective positive allosteric modulator of the AMPA-type glutamate receptor. The key word is *modulator*, not *agonist*. According to PubMed, in the foundational preclinical work it potentiated AMPA-receptor signaling with virtually no agonistic activity of its own, which is why the authors describe it as an AMPA potentiator with minimal agonism PMID: 34655652 (DOI). That distinction is the whole design thesis, and it matters for everything downstream.
People lump it in with "ampakines," and mechanistically that is fair. It is in the same broad family as CX-516 and other AMPA potentiators. But the older ampakines had a narrow bell-shaped dose-response curve and a seizure liability, because at higher doses they started acting more like agonists and drove runaway excitation. Selecting for potentiation without agonism is the design feature meant to widen the margin against those seizures, and it is the trait the preclinical characterization of TAK-653 emphasizes PMID: 34655652 (DOI). So TAK-653 is best described as an ampakine-like compound built to avoid the reasons ampakines never made it.
Names are a source of confusion, so here they are in one place:
| Name | What it refers to |
|---|---|
| TAK-653 | Original Takeda development code |
| Osavampator | Assigned generic (INN) name |
| NBI-1065845 | Neurocrine's code after licensing |
All three are the same molecule.
How it works
The proposed mechanism runs through synaptic plasticity, not through the monoamine systems that classic antidepressants target. According to PubMed, in rat primary cortical neurons TAK-653 increased the phosphorylated, activated forms of mTOR and p70S6 kinase, along with their upstream regulators Akt and ERK, and it raised BDNF protein levels PMID: 34655652 (DOI). That BDNF-and-mTOR cascade is the same signaling pathway implicated in ketamine's rapid antidepressant action.
A 2025 review lays out the convergent logic for AMPA-receptor PAMs, osavampator among them: increased AMPA-receptor activation triggers BDNF release and mTOR signaling, which promotes synaptic strengthening through more AMPA-receptor trafficking and new dendritic spine formation PMID: 40840695 (DOI). In plain terms, the idea is that you nudge the brain's excitatory signaling just enough to trigger the machinery that builds and reinforces synapses.
There is also a genuinely clever human biomarker here. According to PubMed, single- and paired-pulse transcranial magnetic stimulation (TMS) of the motor cortex was used as a translational pharmacodynamic readout. In healthy volunteers TAK-653 increased the amplitude of motor-evoked potentials, a marker of cortical excitability consistent with AMPA-receptor potentiation, at plasma concentrations comparable to active doses in rats. It did not change resting motor threshold or paired-pulse responses PMID: 34045439 (DOI). That gave the developers a way to confirm the drug was hitting its target in a living human brain, not just in a dish.
The real clinical evidence
Human data on TAK-653 is early but not vaporware. There are published Phase 1 studies and a Phase 2 depression trial, and it is worth separating what is peer-reviewed from what is only in press releases.
On the Phase 1 side, a randomized, double-blind, placebo-controlled three-way crossover study in 24 healthy volunteers (placebo vs 0.5 mg vs 6 mg) tested functional CNS effects using the NeuroCart battery. According to PubMed, TAK-653 produced a psychostimulant-like profile: it improved adaptive tracking at 6 mg and increased saccadic peak velocity and smooth pursuit, without the body sway, sedation, or subjective drug effects you see with CNS depressants PMID: 36153330 (DOI). Combined with the TMS biomarker work, that is a consistent picture of a compound that raises cortical excitability in a controlled, alert-leaning way.
The bigger news is Phase 2. Neurocrine ran a randomized, double-blind, placebo-controlled dose-finding study (SAVITRI) of once-daily oral osavampator as an add-on for adults with major depressive disorder who had responded inadequately to standard antidepressants. The company reported a statistically significant improvement on the MADRS depression scale over placebo, with the effect building further out to Day 56.
Where does that leave the honest evidence level? Solid, well-characterized mechanism. Clean Phase 1 human neurophysiology, peer-reviewed. A positive but not-yet-peer-reviewed Phase 2 signal in depression. A drug that has advanced into a Phase 3 registrational program. That is genuinely promising for an experimental antidepressant, and it is also nowhere near "proven." No long-term human safety data exists.
TAK-653 vs ketamine vs older ampakines
The cleanest way to place TAK-653 is against the two things people compare it to: ketamine (the current reference point for rapid-acting, glutamate-based antidepressants) and the older ampakines it descends from.
The link to ketamine is mechanistic and specific. According to PubMed, ketamine's antidepressant effect starts upstream at the NMDA receptor, but it is blocked by the AMPA antagonist NBQX, which shows AMPA-receptor activation is the shared downstream node. TAK-653 engages that AMPA node directly. And unlike ketamine, it did not produce a hyperlocomotor response in rats, a proxy for the psychotomimetic side effects that make ketamine what it is PMID: 34655652 (DOI). Practically, TAK-653 is an oral once-daily pill, not a dissociative anesthetic given under monitoring.
A broader pharmacology review frames AMPA-receptor potentiation as a general triggering mechanism shared across rapid-acting antidepressants and names TAK-653 as an AMPA potentiator in clinical development PMID: 31378256 (DOI). And a review of emerging non-monoamine psychiatric drugs positions TAK-653 (NBI-1065845) alongside zuranolone and Auvelity as part of the shift away from monoamine mechanisms, aimed at treatment-resistant or inadequate-response depression PMID: 38868733 (DOI).
| Compound | Mechanism | Route / class | Development stage | Note |
|---|---|---|---|---|
| TAK-653 (osavampator) | AMPA-R positive allosteric modulator, minimal agonism | Oral, once-daily small molecule | Phase 3 program for MDD; not approved | Designed to avoid ampakine seizure/bell-curve liability PMID: 34655652 |
| Older ampakines (e.g. CX-516) | AMPA-R potentiators with more agonist-like action | Oral | Largely stalled in development | Narrow dose window, seizure/bell-shaped-curve concerns |
| Ketamine / esketamine | NMDA-R antagonist; downstream effect blocked by AMPA antagonist | IV / intranasal, clinic-administered | Esketamine FDA-approved for TRD | Dissociative; psychotomimetic effects; acute monitoring PMID: 34655652 |
How it is used and studied
Here is where research-published facts and community folklore diverge, so I'll keep them clearly separated.
From published studies and trials. The Phase 1 human neurophysiology studies tested single oral doses of 0.5 mg and 6 mg versus placebo PMID: 36153330 (DOI) PMID: 34045439 (DOI). The Phase 2 SAVITRI trial used once-daily oral dosing in the low-milligram range. A drug-interaction study used multiple once-daily doses over about two weeks PMID: 38700236 (DOI). The reported terminal half-life is long, roughly 33 to 48 hours per secondary drug databases rather than the PubMed abstracts reviewed here, which is consistent with once-daily dosing because the compound accumulates and does not need to be taken multiple times a day.
From the research community. Osavampator/TAK-653 gets a lot of attention in nootropic and biohacker circles, mostly because it is a clean AMPA-receptor PAM without the seizure and desensitization baggage of older ampakines. Anecdotal write-ups tend to center on cognition; people report sharper focus, better verbal fluency, and improved working memory. The framing of it as "one of the most potent nootropics" shows up mainly on vendor and marketing pages, not in peer-reviewed sources, so treat those superlatives with skepticism.
I'm reporting what studies and forums describe, not telling you to dose anything. TAK-653 is investigational.
Safety, honestly
TAK-653/osavampator is not approved by the FDA or any regulator for any use. The entire human safety database is small and short-term: Phase 1 studies in a few dozen healthy volunteers, and one Phase 2 add-on trial in adults with major depressive disorder run over about eight weeks. There is no long-term human safety data, and no data at all in the off-label nootropic-user population.
The class-level concern is that AMPA-receptor potentiators can lower seizure threshold. TAK-653 was specifically designed with minimal agonism to reduce that risk and did not show the classic bell-shaped seizure liability in preclinical work, but you cannot assume the risk is zero, especially at supratherapeutic doses or in people with seizure risk factors. Company materials describe headache as a commonly reported adverse event with an overall profile they characterize as comparable to placebo, and those figures are from Phase 2 press communications, not yet peer-reviewed.
On drug interactions, there is one useful published data point. According to PubMed, a Phase 1 study found NBI-1065845 is not a CYP3A inducer and did not meaningfully change exposure of the CYP3A substrate midazolam or of a combined oral contraceptive (ethinyl estradiol/levonorgestrel) PMID: 38700236 (DOI). That is reassuring for those specific combinations, but it does not clear the compound for stacking with antidepressants or other CNS drugs. Comprehensive interaction, pregnancy, and combination safety data outside controlled trials simply do not exist. Anyone on psychiatric medication should not assume this is safe to add. This is not medical advice.
Sourcing and storage
TAK-653 is a small-molecule capsule compound, not a peptide, so there is no reconstitution step. Storage is simple: keep it cool, dry, and dark. None of the peptide-handling workflow applies here, though the same purity-verification logic does.
Because this is a research chemical with no regulatory oversight of what is actually in the capsule, the single most important thing is a per-lot certificate of analysis (COA). One reputable option that publishes COAs per lot is BHG Labs, which lists TAK-653 Capsules in stock: TAK-653 Capsules at BHG Labs. Use code REDDIT for 10% off. *Independent vendor; BodyHackGuide may earn a commission.* BHG Labs is an independent third-party vendor ("BHG" here does not mean BodyHackGuide), and it is one option among several, not the only place to buy. Whatever source you use, insist on a lot-matched COA and learn to read it. Our guides on how to read a peptide COA and the vendor scorecard apply to any research compound, capsules included.
For the compound overview and current price comparison, see the TAK-653 compound page. If you're new to handling research compounds generally, the peptide storage guide covers cold-chain and light-protection basics that carry over.
Frequently asked
Weekly drops, weekly research
New guides, price-drop alerts, and reader-submitted protocols. One email a week. Unsubscribe anytime.
No spam. Unsubscribe anytime.
Discussion
Sign in to join the discussion
No comments yet โ be the first to share your thoughts!